Basiliximab

巴利昔单抗

Report date: 2022/08/16 20:00:19

Base Information

Drug NameBasiliximab
Drug Alias NameChimeric RFT5巴利西单抗舒莱SimulectSDZ-CHI-621 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionInterleukin-2 receptor alpha chain inhibitors
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsRejection of organ transplantationRejection of renal transplantationCoronavirus Disease 2019 (COVID-19) +[21] 
Global Approved IndicationsRejection of organ transplantationRejection of renal transplantation
Approved Indications in ChinaRejection of renal transplantation
Original Approved Country/TerritoryUnited States
Original Approved Date1998/05/12
Country/TerritoryCzechiaBelgiumCanada +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Schweiz AgNovartis Pharma AgNovartis Europharm Ltd
Inactive CompaniesDrexel University College of MedicineUniversity Medical Center FreiburgResearch Institute Of The Mcgill University Health Centre +[8] 
Active IndicationsRejection of organ transplantationRejection of renal transplantation
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Keratoplasty rejectionCytokine Release Syndrome +[19] 

Other Information

ATC CodeL04AC02
Related LinksWikipediaDrugBankKEGG